The World In A Grain Of Sand: CG Oncology The World In A Grain Of Sand podcast

Contenu fourni par KdT Ventures. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par KdT Ventures ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

The World In A Grain Of Sand »
The World in a Grain of Sand: CG Oncology

5M ago 43:43

M4A•Maison d'episode

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into:

The various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease
Supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer
CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer
Challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s lead asset
Bull vs bear case for CG Oncology

For updates from KdT, ⁠⁠subscribe to our Substack⁠⁠.

13 episodes

#Trading #Business #KdT Ventures